How to increase AAV production with a novel enhancer designed for use with any transfection reagent in any suspension HEK cell

Live30 webinars are thirty-minute presentations designed to update you on the latest innovations, applications, and data in a fast yet interactive format.

With the success of cell and gene therapies and exponentially increasing demand, the second wave of viral vector manufacturing is focused on large-scale suspension cell culture. Upstream manufacturing processes for recombinant adeno-associated virus (AAV) and lentivirus (LV) are largely dependent on transient transfection of multiple plasmid DNA constructs encoding essential viral proteins. To produce the virus needed for these therapies, processes must be adapted to bioreactor scale for cGMP production.

In response to this need, Mirus Bio has already established a novel transfection reagent that increases AAV and LV titers 2-10-fold over existing technologies. The focus of this talk is the development of an enhancer that further increases AAV production by up to 2-3-fold with any transfection reagent, in any HEK 293 cell type, and for any serotype. Important characteristics were considered during reagent and enhancer development to ensure scalability, straightforward optimization, and seamless adoption within AAV manufacturing.

• Learn to increase AAV production across multiple transfection reagents
• Assess the impact of the novel enhancer across multiple serotypes, including AAV2, AAV5, AAV8, and AAV9 (based on data from both internal and customer testing)
• Review the recommended protocol and amounts of enhancer to use within AAV workflows
• Understand how higher AAV production leads to lower costs per dose
• What support is available for evaluating and using the enhancer in your process

Leisha Kopp

Senior Field Applications Scientist at Mirus Bio

Leisha Kopp is a Senior Field Applications Scientist at Mirus Bio, a company committed to equipping biopharmaceutical innovators with next generation transfection solutions for all cell culture applications. Leisha has 20 years of molecular biology and mammalian cell culture experience in industrial labs and has worked extensively with an array of primary and immortalized mammalian cells. Her combined bench and biopharma knowledge enables support of scientists in all stages of the drug discovery process to develop optimized and scalable processes that deliver complex therapies to patients more quickly. Leisha is a graduate of the University of Wisconsin-Madison, with key interests in viral vector manufacturing and gene therapy.

Watch now

SPEAKERS

Leisha Kopp

Senior Field Applications Scientist at Mirus Bio

You might also like

Same-section spatial multiomics: a platform for detailed analysis of the solid tumor TME

Emily Neil, Ariadna Pascual

27 June

in 54

Days

Register

Specifications don’t tell the whole story: how to choose GMP process and QC equipment

M Kay Bates, W Marin, K Whitlatch

18 June

in 45

Days

Register

Quadplex dPCR as a tool to analyze genome integrity and heterogeneity in gene therapy drug products

Ryan Massopust

11 June

in 38

Days

Register

Precision in production: optimizing monitoring and quality control for high-value plasmids

Oleksandr Karpenko

6 June

in 33

Days

Register

Advancing cell therapy: innovations in polymer-based encapsulation and delivery

Y Brudno, O Veiseh, M Delic-Schlumbohm et al.

5 June

in 32

Days

Register